Posted by Michael Wonder on 07 Aug 2019
Proposal for funding of oncology, multiple sclerosis and respiratory treatments
7 August 2019 - PHARMAC is seeking feedback on a proposal to fund three new treatments and widen access to one currently funded treatment through a provisional agreement with Roche Products (NZ) Limited (Roche).
In summary, this proposal would result in the following changes from 1 December 2019:
Funding of three new treatments:
- alectinib (Alecensa) for ALK positive advanced non-small cell lung cancer
- trastuzumab emtansine (Kadcyla) for HER-2 positive metastatic breast cancer
- ocrelizumab (Ocrevus) for relapsing remitting multiple sclerosis
Amendment to the listing of pirfenidone (Esbriet) for idiopathic pulmonary fibrosis to:
- widen access for patients with a forced vital capacity of up to 90%
- list a new 801 mg tablet presentation
